Login to Your Account

Cephalon Inks Bargain-Priced Option for Alba's Celiac Drug

By Jennifer Boggs

Friday, February 11, 2011
Looking to pad its immunology portfolio, Cephalon Inc. paid $7 million to pick up an option for midstage celiac disease candidate larazotide acetate from struggling private biotech Alba Therapeutics Inc.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription